Aastrom Biosciences Inc. (Nasdaq: ASTM) reported disappointing results from a midstage clinical trial of its critical limb ischemia treatment sending the stock price plummeting $1.49 to close at $2.71.
Disappointing Trial Results For Aastrom Biosciences
November 18, 2010 at 18:09 PM EST
